Targeting the ERBB family in cancer: couples therapy N Tebbutt, MW Pedersen, TG Johns Nature Reviews Cancer 13 (9), 663-673, 2013 | 498 | 2013 |
The type III epidermal growth factor receptor mutation: biological significance and potential target for anti-cancer therapy MW Pedersen, M Meltorn, L Damstrup, HS Poulsen Annals of oncology 12 (6), 745-760, 2001 | 344 | 2001 |
Sym004: a novel synergistic anti–epidermal growth factor receptor antibody mixture with superior anticancer efficacy MW Pedersen, HJ Jacobsen, K Koefoed, A Hey, C Pyke, JS Haurum, ... Cancer research 70 (2), 588-597, 2010 | 269 | 2010 |
The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers GG Duthie, MW Pedersen, PT Gardner, PC Morrice, AME Jenkinson, ... European Journal of Clinical Nutrition 52 (10), 733-736, 1998 | 244 | 1998 |
EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes MV Grandal, R Zandi, MW Pedersen, BM Willumsen, B van Deurs, ... Carcinogenesis 28 (7), 1408-1417, 2007 | 197 | 2007 |
Activation of the EGFR gene target EphA2 inhibits epidermal growth factor–induced cancer cell motility AB Larsen, MW Pedersen, MT Stockhausen, MV Grandal, B Deurs, ... Molecular cancer research 5 (3), 283-293, 2007 | 168 | 2007 |
Transcriptional gene expression profiling of small cell lung cancer cells N Pedersen, S Mortensen, SB Sørensen, MW Pedersen, K Rieneck, ... Cancer research 63 (8), 1943-1953, 2003 | 135 | 2003 |
Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a … C Montagut, G Argilés, F Ciardiello, TT Poulsen, R Dienstmann, M Kragh, ... JAMA oncology 4 (4), e175245-e175245, 2018 | 110 | 2018 |
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor K Koefoed, L Steinaa, JN Søderberg, I Kjær, HJ Jacobsen, PJ Meijer, ... MAbs 3 (6), 584-595, 2011 | 109 | 2011 |
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility MW Pedersen, V Tkach, N Pedersen, V Berezin, HS Poulsen International journal of cancer 108 (5), 643-653, 2004 | 103 | 2004 |
Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro J Vestergaard, MW Pedersen, N Pedersen, C Ensinger, Z Tümer, ... Lung cancer 52 (3), 281-290, 2006 | 98 | 2006 |
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII MW Pedersen, N Pedersen, LH Ottesen, HS Poulsen British journal of cancer 93 (8), 915-923, 2005 | 88 | 2005 |
Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity HJ Jacobsen, TT Poulsen, A Dahlman, I Kjær, K Koefoed, JW Sen, ... Clinical Cancer Research 21 (18), 4110-4122, 2015 | 85 | 2015 |
Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer R Dienstmann, A Patnaik, R Garcia-Carbonero, A Cervantes, M Benavent, ... Cancer Discovery 5 (6), 598-609, 2015 | 82 | 2015 |
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab M Iida, TM Brand, MM Starr, C Li, EJ Huppert, N Luthar, MW Pedersen, ... Neoplasia 15 (10), 1196-1206, 2013 | 74 | 2013 |
Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation MW Pedersen, N Pedersen, L Damstrup, M Villingshøj, SU Sønder, ... Journal of cellular biochemistry 96 (2), 412-427, 2005 | 71 | 2005 |
The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer N Pedersen, MW Pedersen, MS Lan, MB Breslin, HS Poulsen Cancer gene therapy 13 (4), 375-384, 2006 | 65 | 2006 |
Oncology drug innovation H Poulsen, N Pedersen, S Mortensen, S Sorensen, M Pedersen, H Elsner US Patent App. 10/482,029, 2005 | 63 | 2005 |
EGFR induces expression of IRF‐1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells P Andersen, MW Pedersen, A Woetmann, M Villingshøj, MT Stockhausen, ... International journal of cancer 122 (2), 342-349, 2008 | 62 | 2008 |
Targeting three distinct HER2 domains with a recombinant antibody mixture overcomes trastuzumab resistance MW Pedersen, HJ Jacobsen, K Koefoed, A Dahlman, I Kjær, TT Poulsen, ... Molecular Cancer Therapeutics 14 (3), 669-680, 2015 | 60 | 2015 |